Table 2

Prospective risk of cancers in CDKN2A p.Arg112dup carriers (n=120) compared with non-carriers (n=111) and controls (n=3976)

Tumour typep.Arg112dupNon-carriersControls
observedexpected*RR (95% CI)expected*RR (95% CI)
Melanoma353.619.7 (3.5 to 27.2)0.5464.8 (36.9 to 117.9)
Pancreas70NA†0.1643.8 (13.8 to 139.0)
Digestive—upper60NA†0.3517.1 (6.3 to 46.5)
Respiratory50.905.6 (0.7 to 47.4)0.3215.6 (5.4 to 46.0)
Gynaecological73.611.9 (0.6 to 6.6)0.808.8 (3.8 to 20.4)
Haematopoietic or lymphatic20NA†0.513.9 (0.6 to 10.6)
CNS10NA†0.293.4 (0.4 to 27.5)
Skin (non-melanoma)30.903.3 (0.3 to 31.9)0.923.3 (1.0 to 10.7)
Breast30.903.3 (0.3 to 31.9)0.993.0 (0.9 to 9.9)
Endocrine10NA†0.352.9 (0.4 to 22.1)
Urinary30.903.3 (0.3 to 31.9)1.751.7 (0.5 to 5.5)
Digestive—lower10NA†0.961.0 (0.1 to 7.7)
Connective tissue00NA†0.030.0
Unknown primary tumour00NA†0.290.0
All non-melanoma cancers398.124.8 (2.4 to 10.1)7.785.0 (3.7 to 7.3)
  • *In non-carriers and controls, numbers of expected cases are calculated to correspond to equal person years as for carriers.

  • †NA=RR not calculable since 0 cases of cancer type in non-carriers.

  • RR, Relative risk.